CN109369579A - A kind of preparation of new compound and its application in terms for the treatment of of cancer - Google Patents
A kind of preparation of new compound and its application in terms for the treatment of of cancer Download PDFInfo
- Publication number
- CN109369579A CN109369579A CN201811299205.9A CN201811299205A CN109369579A CN 109369579 A CN109369579 A CN 109369579A CN 201811299205 A CN201811299205 A CN 201811299205A CN 109369579 A CN109369579 A CN 109369579A
- Authority
- CN
- China
- Prior art keywords
- cancer
- compound
- cell
- application according
- stat3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 47
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 34
- 201000011510 cancer Diseases 0.000 title claims abstract description 28
- 238000011282 treatment Methods 0.000 title abstract description 15
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 10
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 9
- 201000005202 lung cancer Diseases 0.000 claims abstract description 9
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 9
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 8
- 208000032839 leukemia Diseases 0.000 claims abstract description 8
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims abstract description 6
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims abstract description 6
- 230000004715 cellular signal transduction Effects 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 239000002262 Schiff base Substances 0.000 claims description 9
- -1 Gold methyl ester Chemical class 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 6
- 150000004753 Schiff bases Chemical class 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims description 5
- HYBBIBNJHNGZAN-UHFFFAOYSA-N Furaldehyde Natural products O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 claims description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- KZTWONRVIPPDKH-UHFFFAOYSA-N 2-(piperidin-1-yl)ethanol Chemical compound OCCN1CCCCC1 KZTWONRVIPPDKH-UHFFFAOYSA-N 0.000 claims description 3
- 239000010931 gold Substances 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 230000036571 hydration Effects 0.000 claims description 2
- 238000006703 hydration reaction Methods 0.000 claims description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 10
- 238000011160 research Methods 0.000 abstract description 5
- 230000007246 mechanism Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 230000003828 downregulation Effects 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000008844 regulatory mechanism Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 21
- 239000003814 drug Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical class COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 11
- 238000003032 molecular docking Methods 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000009514 concussion Effects 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229940095102 methyl benzoate Drugs 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229960000935 dehydrated alcohol Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229920001821 foam rubber Polymers 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 238000012827 research and development Methods 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940096437 Protein S Drugs 0.000 description 3
- 108010002687 Survivin Proteins 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 239000012160 loading buffer Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 102000000763 Survivin Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 229940080856 gleevec Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000006948 antiviral bioactivity Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 102000055104 bcl-X Human genes 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/70—Nitro radicals
- C07D307/71—Nitro radicals attached in position 5
- C07D307/72—Nitro radicals attached in position 5 with hydrocarbon radicals, substituted by nitrogen-containing radicals, attached in position 2
- C07D307/74—Nitro radicals attached in position 5 with hydrocarbon radicals, substituted by nitrogen-containing radicals, attached in position 2 by hydrazino or hydrazono or such substituted radicals
- C07D307/75—Nitro radicals attached in position 5 with hydrocarbon radicals, substituted by nitrogen-containing radicals, attached in position 2 by hydrazino or hydrazono or such substituted radicals having carboxylic acyl radicals or their thio or nitrogen analogues directly attached to the hydrazino or hydrazono radical, e.g. hydrazides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to biomedicine fields, provide a kind of application of the design and preparation method and the compound of new compound in terms of cell growth control mechanism and treatment of cancer.Shown by biological activity test, compound of the present invention has significant negative regulation to act on STAT3 cellular signal transduction, and there is significant inhibiting effect to the proliferation of a variety of cancer cells such as lung cancer, breast cancer, colon cancer and leukaemia, it is shown that the compound has potential significance to clinical treatment and cell the regulatory mechanism research of cancer.The compound great exploitation potential, has a good application prospect, preparation method simple process, needs easy to implement, being suitble to scale industrial production.
Description
Technical field
The present invention relates to biomedicine field, more particularly to a kind of preparation of novel acylhydrazone schiff base compounds and
Application in terms for the treatment of of cancer.
Background technique
The newest cancer data of China of National Cancer Center publication in 2017 is shown, in China, annual new cancer cases
Up to 4,290,000, the 20% of global new cases is accounted for, dead 2,810,000.Lung cancer is the cancer of disease incidence, the double rates first of the death rate, cream
Gland cancer is the highest cancer of women's tumor incidence.The morbidity and mortality of colon cancer and leukaemia also remain high.Cancer
Have become one of the factor for influencing Chinese national health and causing heavy economic losses.The method-of traditional treatment cancer is performed the operation, is put
It treats, chemotherapy and biological therapy have certain limitation (newest cancer data of China in 2017 to the control of the tumour patient state of an illness
[J] China's clinical tumor and rehabilitation, 2017 (5): 574-574).2001, the appearance of first generation targeted drug-Gleevec was given
The clinical treatment of cancer patient brings new favourable turn and hope.The anticancer targeting medicine of the newest listing in the world in 2017 is in China
Occupation rate of market only 1% or so.5 anti-cancer drugs of Chinese food Drug Administration (CFDA) reply listing in 2017 do not have
There is an innovation target spot, the original targeting new drug of China is very few, totally reflects the domestic research and development water for targeting original drug
It is American-European after falling to normal price.How to accomplish that " double wounds " (biological targets are relevant to disease to control for the first time for clinic in terms of medicament research and development
The novel targets and novel compounds for the treatment of) it is the touchstone for testing our Chinese Medicine research and development strength.Seek new target spot and has latent
The lead compound of power has breakthrough in terms of specific clinical therapy of tumor, is medicine research and development scientific research personnel when business
It is anxious.The excited growth and breeding for promoting kinds of tumor cells of JAKs-STAT3 signal transduction, tumour relevant to STAT3 includes head
Neck cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, chronic myelocytic leukemia, acute myeloblastic leukemia and multiple
Myeloma etc..U.S. Food and Drug Administration (FDA) given an written reply in the clinical trial stage based on STAT3 albumen target spot
Anticancer drug up to more than 30, recent clinical test results show that such drug is huge in terms of future tumors clinical treatment
Potentiality and the open market space (Johnson D E., et al., Nature Reviews Clinical Oncology,
2018,15 (4): 234).It is found by the applicant that schiff base compounds belong to STAT3 inhibitor, such compound inhibit STAT3 it is thin
The mechanism of born of the same parents' signal transduction activation is clear, induces the significant effect of associated tumor cells apoptosis.STAT3 inhibitor class anti cancer target
The features such as drug has target spot new and anticancer spectrum width.This compound is researched and developed by Henan Province is sharp up to Pharmaceutical Technology Co., Ltd.
Schiff base compounds are because its unique structure feature, i.e. core group contain the N atom with lone pair electrons, to have
There is good pairing ability, and the group both sides can react to obtain the different derivative of property with various types of groups
Object, this makes it very characteristic in practical application, is especially widely used in terms of chemistry, biology.Schiff bases containing O, S, N
And its metal complex, the attention of people is constantly subjected to its good antibacterial, anticancer and antiviral bioactivity.Especially
Research of the Ercefuryl in terms for the treatment of of cancer had certain progress (Nelson E A., et al., Blood, 2008,
112 (13): 5095-5102).
The present inventor intends to solve clinical cancer targeted therapy problem.Advanced drug evaluation system and preparation in the reference world
While technique, the targeting type for grinding management regulation and the clinical Chinese independent intellectual property rights of method for transformation exploitation with its efficient medicine is new
Medicine.Compound of the present invention belongs to Schiff bases, and synthesis cost is cheap, it is contemplated that and price is only the 1/3 of Conmana price,
The 1/20 of Gleevec, researches and develops the novel targets targeting type new drug for being successfully expected to achieve Chinese first independent research, and feature is to treat
Imitate significant, broad spectrum anticancer and lower-price characteristic.
Summary of the invention
The main purpose of the present invention is to provide a kind of preparations of New Schiff Base class compound, novel high living as STAT3
Property, application of the hypotoxicity inhibitor in terms for the treatment of of cancer.
For achieving the above object, the present invention provides the preparation of the compound of general formula and treatment of cancer sides
The application in face.
One aspect of the present invention is related to the preparation method of above compound, includes the following steps:
I) using nepal Gold methyl ester as raw material, by itself and N- piperidine ethanol, triphenylphosphine dissolved is cold in tetrahydrofuran
To 0 DEG C, then diisopropyl azodiformate is slowly added dropwise, reaction is finally stirred at room temperature overnight, obtains intermediate
(II):
Ii intermediate (II) and hydration hydrazine reaction 12h) are obtained into intermediate (III):
Iii intermediate (III)) is reacted into 12h with 4- nitryl furfural and obtains compound described in claim 1:
Wherein, the heating temperature refers to 50-100 DEG C.
The purpose of the present invention is find with high STAT3 inhibiting effect and with the noval chemical compound of low toxicity.
The present invention relates to above-mentioned compound 4- (2- (piperidin-1-yl) ethyoxyl) methyl benzoate derivatives, its pharmacy
The solvate of upper acceptable salt, the solvate of the derivative or the salt is controlled in preparation for treating or assisting
Purposes in treatment/or prevention mammal in the drugs such as lung cancer, breast cancer, colon cancer and leukaemia.Specifically, the lactation
Animal is the mankind.
Another aspect of the present invention is related to above-mentioned compound 4- (2- (piperidin-1-yl) ethyoxyl) methyl benzoate and spreads out
The solvate of biology, the solvate of its pharmaceutically acceptable salt, the derivative or the salt is in preparation for controlling
All tumor cell proliferations relevant to STAT3 cellular signal transduction and migration in treatment or adjuvant treatment/or prevention mammal
Purposes in drug.Specifically, the mammal is the mankind.
Another aspect of the present invention is related to above-mentioned compound 4- (2- (piperidin-1-yl) ethyoxyl) methyl benzoate and spreads out
The solvate of biology, the solvate of its pharmaceutically acceptable salt, the derivative or the salt is in preparation for controlling
Purposes in treatment or adjuvant treatment/or prevention mammal in all diseases relevant to STAT3 cellular signal transduction.Specifically
Ground, the mammal are the mankind.
The present invention will be further described below.
All documents recited in the present invention, their full content are incorporated by reference into the present invention, and if these
Meaning expressed by document and when the inconsistent present invention, is subject to statement of the invention.In addition, the various terms that the present invention uses
With phrase have well known to a person skilled in the art general senses, nonetheless, the present invention is remained desirable at this to these terms
It is described in more detail and explains with phrase, the term and phrase referred to is if any inconsistent with common art-recognized meanings, with institute of the present invention
Subject to the meaning of statement.
In the method for synthetic compound of formula i of the present invention, the various raw material for reacting used are those skilled in the art's roots
It can be prepared according to existing knowledge, or can be made from the method as well known to document, or quotient can be passed through
What industry was bought.Intermediate used in the above reaction scheme, raw material, reagent, reaction condition etc. can be according to this field skills
Art personnel, which have knowledge and can make, suitably to be changed.
Compound of formula I of the invention can be applied in combination with other active components, as long as it does not generate other detrimental effects,
Such as allergic reaction.
Reactive compound shown in formula I can be used as anticancer drug exclusive use, or can with it is one or more
Other anti-tumor drugs are used in combination.Combination therapy by by each therapeutic component simultaneously, sequence or separate administration and realize.
Detailed description of the invention
Fig. 1 is STAT3 (Signal Transducer and Activator of Transcription Type-3) letter
Number conducting system schematic diagram: cell factor (Cytokine) triggers Dimerized (dimerization) of receptor in conjunction with receptor
Or polymer (oligomerization), and make JAKs phosphorylation (phosphorylation) to activating STAT3 signal,
Make STAT3 is attached to combine on receptor by the phosphorylation of the specific tyrosine of the termination environment C in recipient cell after birth；After autophosphorylation,
STAT3 forms the binary parallel conformation of bidirectional crossed interaction；It wears in film transporte to cells core, and starts with specific DNA
Son combines, and induces the expression of related anti-apoptotic gene Bcl-2, Survivin, Bcl-XL and c-Jun etc..
Fig. 2 a is compound HN2SM-001 structural formula in embodiment 1；Fig. 2 b is compound HN2SM-001 in embodiment 1
Nuclear-magnetism figure.
Fig. 3 is the experiment knot of compound HN2SM-001 and the virtual molecular docking of STAT3 Protein S H2 functional domain in embodiment 1
Fruit, compound HN2SM-001 are presented on functional domain activated interface, and nonpolar hydrogen atom (H) is unmarked, in STAT3 albumen
Above the section SH2, have with the key amino acid of HN2SM-001 interaction of molecules: lysine 591 and arginine 609 and silk ammonia
Acid 611,613,636 and glutamic acid 612,638 respectively with LYS591, ARG609, SER611, GLU612, SER613, SER636 and
GLU638 label；The β-pleated sheet in the section STAT3 Protein S H2, α spiral and random coil are respectively with delaying straight band, hurricane band and tubule
It indicates.It is virtually docking the results show that compound HN2SM-001 and STAT3 Protein S H2 functional domain phosphorylation site
ARG609, specific amino acid GLU638 and the hydrophobic selection cavity of drug have strong interaction, infer the compound for effect
STAT3 signal transduction inhibitor in STAT3 phosphorylation site.
Fig. 4 is compound HN2SM-001 induced breast cancer cancer cell line apoptosis MTT experiment, the knot of MTT cell experiment in figure
Fruit is characterized with IC50 (μM) value.Should the experimental results showed that, compound HN2SM-001 can effectively induced breast cancer MDA-MB-
The apoptosis of 231 and MCF-7 cell strain.
Fig. 5 is compound HN2SM-001 induction colon cancer cancer cell line apoptosis MTT experiment, the knot of MTT cell experiment in figure
Fruit is characterized with IC50 (μM) value.Should the experimental results showed that, compound HN2SM-001 can effectively induce colon cancer HCT-116
With the apoptosis of HT-29 cell strain.
Fig. 6 is compound HN2SM-001 inducing leukemia cell strain apoptosis MTT experiment, the result of MTT cell experiment in figure
It is characterized with IC50 (μM) value.Should the experimental results showed that, compound HN2SM-001 can effectively inducing leukemia MOLT-13 and
The apoptosis of Jurkat cell strain.
Fig. 7 is compound HN2SM-001 induction lung cancer cell line apoptosis MTT experiment, in figure the result of MTT cell experiment with
IC50 (μM) value is characterized.Should the experimental results showed that, compound HN2SM-001 can effectively induce lung cancer PC9 and HCC827 thin
The apoptosis of born of the same parents' strain.
Table 1 is that the IC50 value that compound HN2SM-001 inhibits the increment of different type cell strain summarizes.
The IC50 value that 1 HN2-SM-001 of table inhibits the increment of different type cell strain
Fig. 8 is the result of compound HN2SM-001 protein immunoblot.The result of protein immunoblot experiment is with by electrophoresis
Total cellular protein after separation is transferred on solid support film from gel, according to the special principle of antigen-antibody, is passed through respectively
The corresponding expressing quantity of STAT3, p-STAT3, β-Actin antibody test.As a result as schemed, it can be seen that acted in different pharmaceutical
Under, increase with drug concentration, the expressing quantity of STAT3 and β-Actin is constant, and p-STAT3 expression quantity is on a declining curve, changes
Close the expression that object HN2SM-001 obviously inhibits p-STAT3.
Fig. 9 is compound HN2SM-001 inverse transcription polymerase chain reaction test (PCR) result.Utilize sxemiquantitative RT-
The related anti-tune of PCR measurement dies expression conditions, after verifying drug various concentration acts on MDA-MB-231, the expression of related gene
Situation.After the drug effect MDA-MB-231 cell of various concentration, inverted by RNA sample extracting, rna content measurement, sample
It records and measures gene expression amount for cDNA, PCR amplification β-Actin and Survivin gene, gel electrophoresis, the anti-tune of comparison dies gene and exists
Expression under the effect of different pharmaceutical concentration.It can be seen that compound HN2SM-001 has obvious inhibition to Survivin expression
Effect.
Specific embodiment
The present invention is further described below by specific preparation embodiment and simulation and biological test example, still,
It is used it should be appreciated that these embodiments and test example are only used for specifically describing in more detail, but should not be understood as being used for
Present invention is limited in any form.
The present invention carries out general and/or specific description to the material and test method arrived used in test.Though
So used many materials and operating method are it is known in the art that still the present invention still exists to achieve the purpose of the present invention
This is described in detail as far as possible.It will be apparent to those skilled in the art that hereinafter, if not specified, material used in the present invention
Material and operating method are well known in the art.
In the present invention, unless otherwise stated, in which: (i) temperature is indicated with degree Celsius (DEG C), is operated under room temperature environment
It carries out；More specifically, the room temperature refers to 20-30 DEG C；(ii) organic solvent is dry with conventional drying method, and the evaporation of solvent makes
It is evaporated under reduced pressure with Rotary Evaporators, bath temperature is not higher than 60 DEG C；(iii) reaction process is tracked with thin-layer chromatography (TLC)；(iv) it produces eventually
Object has satisfied proton magnetic resonance (PMR) (1H-NMR) and mass spectrum (MS) data.
Embodiment 1: the synthesis of compound HN2SM-001
Compound HN2SM-001
1) synthesis of 4- (2- (piperidin-1-yl) ethyoxyl) methyl benzoate:
Nepal Gold methyl ester (1.52g, 10mmol) solid is added N- piperidine ethanol (1.93g, 15mmol), triphenylphosphine
(2.62g, 10mmol) is dissolved in 15mL anhydrous tetrahydro furan and is stirred in ice bath, and azoformic acid is added dropwise in 0.5h
Diisopropyl ester (2mL, 10mmol)；TLC detects fully reacting, and column chromatogram chromatography obtains white solid powder, is 4- (2- (piperidines-
1- yl) ethyoxyl) methyl benzoate.
2) synthesis of 4- (2- (piperidin-1-yl) ethyoxyl) benzoyl hydrazine:
4- (2- (piperidin-1-yl) ethyoxyl) methyl benzoate (2.63g, 10mmol) solid, mixes with 8mL hydrazine hydrate,
80 DEG C of reflux 12h are heated to, acicular crystal is precipitated after being fully cooled, using ethyl alcohol, ether washs respectively, obtains target compound
That is 4- (2- (piperidin-1-yl) ethyoxyl) benzoyl hydrazine.
3) synthesis of 4- (2- (piperidin-1-yl) ethyoxyl) -2- (5- nitrofuran methylene) benzoyl hydrazine:
4- (2- (piperidin-1-yl) ethyoxyl) benzoyl hydrazine (2.63g, 10mmol) is dissolved in 15mL dehydrated alcohol, 5- nitre
Base furfural (2.1g, 15mmol) puts into the solution, 80 DEG C of back flow reaction 10h is heated to, after TLC detects fully reacting, by solution
It pours into 200mL distilled water, there is faint yellow solid precipitation, filter and use recrystallizing methanol solid, obtain faint yellow solid powder
Last 1.76g, i.e. compound HN2SM-001.1H NMR (300MHz, DMSO) δ 12.16 (s, 1H), 8.40 (s, 1H), 7.92 (d, J
=8.7Hz, 2H), 7.81 (d, J=3.8Hz, 1H), 7.26 (d, J=3.5Hz, 1H), 7.10 (d, J=8.6Hz, 2H), 4.22
(s, 2H), 2.88 (s, 2H), 2.64 (s, 4H), 1.56 (s, 4H), 1.43 (s, 2H)
Embodiment 2: molecular docking (docking) experiment
Method: the interaction mechanism in order to verify compound HN2SM-001 Yu STAT3 albumen, inventor use STAT3
Protein template of the phosphorylation tyrosine bond area (pY-705) in the area SH2 as computer virtual simulation (docking), it is empty
Quasi- docking region is concentrated mainly on phosphorylated tyrosine action site ARG609 and LYS591 near zone.The knot of STAT3 SH2
Structure coordinate is taken at Protein structure databases (PDB data bank, ID:1BG1).The method of molecular docking (docking): institute
The experiment of some computer coordination simulations (docking) is completed on the operating platform of sybyl X2.1.1, calculating used
The tool of machine coordination simulation (docking) is SUEFLEX DOCK.It (mainly include that phosphorylated tyrosine is made according to selected site
It is calculated with site ARG609 and LYS591), determine potential energy level (potential gradient) and makees computer coordination mould
The experiment (4-6) of quasi- (docking).Divided according to the score (Score) and conformation of simulation (docking) and interaction
Analysis.
Embodiment 3: induced breast cancer, colon cancer, the MTT experiment of lung cancer and leukaemia cancer cell apoptosis
Method: logarithmic growth phase breast carcinoma cell strain MDA-MB-231 and MCF-7, colon cancer cell line HCT-116 are collected
And HT-29, lung cancer cell line PC9 and HCC827, leukemia cell line Jurkat and MOLT-13 are counted, adjustment cell suspension is dense
Degree is 40000/mL, and 200 μ L cell suspensions, that is, 8000, every hole cell is added in every hole；Cell strain adds compound to handle, dense eventually
Degree is respectively 0.01,0.03,0.1,0.3,1,3,10,30,100 μM of nine gradient, and sets blank control, continues to cultivate 48h；Medicine
After object processing, 100 μ L (1mg/mL) of thiazolyl blue reagent, 37 DEG C of incubation 4h is added in every hole；Liquid in hole is discarded after incubation, is dripped
Then solid carbon dioxide part is added 100ul dimethyl sulfoxide, is reacted 7-8min on horizontal oscillator with filter paper exhaustion Liquid Residue, until blue
Purple crystal is completely dissolved；The OD value for being 570nm in absorbing wavelength with microplate reader measurement, records result.
Embodiment 4: protein immunoblot (Westernblot) experiment
1, cell culture and dosing
(1) logarithmic growth phase MDA-MB-231 cell, after being digested with pancreatin, with the RPMI- for containing 10% fetal calf serum
The single cell suspension that density is 300000/mL is made in 1640 culture mediums, and it is thin to 6 holes that 2mL cell suspension inoculation is added with every hole
In born of the same parents' culture plate.
(2) 37 DEG C, 5%CO2Incubator is incubated for, and after cell is adherent, it is respectively 10,30,60 and 100 μM that final concentration, which is added,
Drug, and set blank control group.After 1h in addition to blank control group, it is 1mg/mL interleukin 6 (IL-6) that concentration, which is added, in each group
30 μ L stimulate cell, interleukin 6 (IL-6) final concentration of 30ng/mL.
2, cell cracking, protein extraction and determining the protein quantity
(1) upper layer culture medium is removed, is washed twice in six porocyte culture plates with phosphate buffer (PBS).Pre-cooling is added
RIPA cell pyrolysis liquid (protease inhibitors, inhibitors of phosphatases and phenylmethylsulfonyl fluoride and lysate are with 1: 100 ratio
Example is added mixes in advance) 100 μ L.Cell pyrolysis liquid is scraped off with cell scraping clean in advance, be collected into one it is clean
In 1.5mL centrifuge tube.
(2) it places on ice, cracks 30min, be vortexed every 6min primary.
(3) 4 DEG C, 12000rpm, it is centrifuged 12min.
(4) after being centrifuged, cell conditioned medium is collected, is divided into two parts: 5 μ L being taken to be added in the centrifuge tube of 1.5mL, be used for BCA
Protein content is surveyed, 1 × phosphate buffer (PBS) mixing for adding 45 μ L is spare；Remaining 60 μ L of cell conditioned medium quantitative,
5 × SDS sample-loading buffer (Loading Buffer) 15 μ L is added, boils 8min after mixing in boiling water, -20 DEG C of ice after centrifugation
It is saved in case.
(5) determination of protein concentration, specific steps:
A, with 1 × phosphate buffer (PBS) diluted protein standard items, table handling is pressed:
B, BCA working solution is prepared: according to the number of standard items and sample to be tested, A needed for calculating in total and B hybrid working
The amount of liquid.In the ratio of BCA reagent A and B volume ratio 50: 1, working solution is prepared, vortex oscillation mixes spare.
C, it by protein standard liquid and the sample supernatant diluted with phosphate buffer (PBS) (10 times of dilutions), respectively takes
25 μ L are added in 96 new orifice plates.Then it is separately added into the BCA working solution that 200 μ L are prepared in advance again, mixes well.Make sure to keep in mind not
Generation bubble is blown and beaten, 96 orifice plate plate lids is covered tightly, reacts 30min in 37 DEG C of insulating boxs.
D, 96 orifice plates are taken out to restore to room temperature, 3-5min, the absorbance value under 562nm wavelength is measured in microplate reader, is made
Out standard curve and 1 μ L/Protein content of each sample is calculated in case albumen loading.
3, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
(1) fixed plastic plate, prepares 12% SDS-PAGE separation gel.
Separation gel: 10mL is prepared according to following table
(2) mixed separation gel is added separately in 2 blocks of offset plates, is added to the position from top 1.0cm, uses dehydrated alcohol
Offset plate is filled up, 30-45min is stood.
(3) after separation gelling is good, remaining dehydrated alcohol is poured out, and blotted remaining dehydrated alcohol only with filter paper.
(4) 5% concentration glue: 5mL is prepared according to following table
(5) prepared concentration glue is slowly added into offset plate, avoids generating bubble, be inserted into sample comb, stands 30-
45min。
(6) protein sample is taken out, 100 DEG C of heating water bath 5min, revolving speed 10000rpm are centrifuged 10min.
(7) offset plate is fixed in electrophoresis tank, SDS-PAGE electrophoretic buffer is added, extract sample comb, in sequence will
The protein sample handled well is added in sample cell.
(8) 80V electrophoresis 40min.
(9) voltage 120V electrophoresis about 1.5h is changed, until bromophenol blue runs out of colloid.
4, transferring film
(1) the SDS-PAGE glue that electrophoresis finishes is put into TBST buffer and is rinsed once, protein adhesive is put into transferring film buffering
It is impregnated in liquid.
(2) one layer of foam-rubber cushion is soaked in film transfer buffer, is clipped on transferring film instrument with tweezers, according to foam-rubber cushion, three
Layer filter paper, protein adhesive, Kynoar (PVDF) film, three layers of filter paper, foam-rubber cushion are sequentially put well, are aligned, are picked up and be put into transferring film instrument
On, when operation, filter paper, foam-rubber cushion are intended to soak in transferring film buffer.If having bubble application teat glass between every layer gently
Rolling is driven out of.
(3) transferring film instrument, 300mA transferring film 75min are opened.
(4) it takes the film out, is put into TBST buffer, the horizontal concussion instrument of 60rpm rinses 3 times, each 8min.
(5) 2h is closed with the horizontal concussion instrument room temperature of 5% bovine serum albumin(BSA) (BSA) confining liquid 20mL, 60rpm.
(6) with the 3mL antibody incubation liquid added with 3 μ L primary antibodies (STAT3 and p-STAT31: 1000), 4 DEG C of 60rpm level shakes
Instrument is swung to be incubated overnight.
(7) 10mL TBST is used, the horizontal concussion instrument of room temperature 60rpm washs pvdf film three times, each 10min.
(8) with the 20mL antibody incubation liquid added with 2 μ L secondary antibodies, the horizontal concussion instrument incubation pvdf membrane 2h of room temperature 60rpm.
(9) 10mL TBST is used, the horizontal concussion instrument of room temperature 60rpm washs pvdf membrane three times, each 10min.
(10) chemiluminescent substrate reagent solution A and solution B each 1mL, color development at room temperature 5min are taken.
(11) liquid on film is blotted with filter paper, is developed.
Embodiment 5: reverse transcriptase polymerase chain reaction tests (RT-PCR)
1, cell culture and dosing:
(1) logarithmic growth phase MDA-MB-231 cell, after being digested by pancreatin, with the RPMI- for containing 10% fetal calf serum
The single cell suspension that density is 100000/mL is made in 1640 culture mediums, and it is thin to 6 holes that 2mL cell suspension inoculation is added with every hole
In born of the same parents' flat-bottomed plates.
(2) 37 DEG C, 5%CO2Incubator is incubated for, and after cell is adherent, replaces fresh culture, experimental group is added containing difference
The drug 10,30,60,100 (μM) of concentration, it is that 1mg/mL interleukin 6 (IL-6) 30 μ L stimulates cell, Bai Jie that concentration is added after 1h
- 6 (IL-6) final concentration of 30ng/mL of element.
(3) after continuing culture for 24 hours, the total serum IgE for extracting group of cells is illustrated according to RNA extracts kit.
2, prepared by RNA sample:
(1) it after culture for 24 hours, discards supernatant, every hole adds TRIZOL 1mL, shakes up, and digests 5min on ice, uses liquid transfer gun head
Piping and druming, draws each boreliquid into 1.5mL centrifuge tube.
(2) plus 0.2mL chloroform, jog 15s are stored at room temperature 3min.
(3) 4 DEG C, 12000rpm centrifugation, 15min.Liquid is divided into three layers after centrifugation, and upper layer is colourless water sample layer RNA, intermediate
White is DNA, and bottom red is protein, and careful upper layer colourless liquid of drawing is transferred in a new centrifuge tube.
(4) it takes honest and upright and thrifty 0.4mL that isometric isopropanol is added, is stored at room temperature 10min.
(5) 4 DEG C, 12000rpm, it is centrifuged 10min.
(6) liquid in centrifuge tube is discarded, 75% ethyl alcohol 1mL is added.
(7) 4 DEG C, 7500rpm, it is centrifuged 5min, carefully discards supernatant, is placed in super-clean bench, forced air drying 5-10min.
(8) 20-30 μ L coke diethyl phthalate (DEPC) aqueous solution is added, it is spare that packing is stored in -70 DEG C of refrigerators.
(9) total serum IgE K5500 ultramicrospectrophotometer detectable concentration and the purity of 2 μ L are taken.According to OD260/OD280
Ratio identify total serum IgE purity.OD260/OD280 illustrates that purity is preferable between 1.8-2.0.
(10) total serum IgE of 5 μ L is taken to mix with 1 μ L of sample-loading buffer, through 1% Ago-Gel (containing GleRed), 120V, electricity
It swims 30min (electrophoretic buffer is 1 × TAE), the quality of RNA is observed under Labworks image acquisition and analysis software.If RNA is feasible without degrading
It tests in next step.
3, the synthesis of cDNA
Reverse transcriptase polymerase chain reaction (Reverse Transcription-Polymerase Chain Reaction,
RT-PCR), experimental principle: the total serum IgE first in extraction group of cells, using mRNA therein as template, in reverse transcriptase
Under catalytic action, synthesized under random primer or poly thymidine (Oligo (dT)) or the guidance of gene-specific primer mutual
The single-stranded cDNA of the DNA of benefit.Again using this cDNA as template, under the guidance of special primer, the PCR amplification for carrying out target gene is anti-
It answers.Since the cDNA is obtained by template reverse transcription of mRNA, so the objective gene sequence of amplification is not comprising introne
Codified gene order.
(1) synthesis of cDNA
A. the centrifuge tube of no RNA enzyme is taken to sequentially add following solution under ice bath:
4 μ L of deoxyribonucleoside triphosphate mixture (dNTP Mix) 2.5mM/each；Primer mixture (Primer
Mix)2μL；RNA template (RNATemplate) 1ug；No RNA enzyme water (RNase-Free Water) adds to 15 μ L.Reaction condition:
70 DEG C of incubations 10min, rapid ice bath 2min.
B. following component is sequentially added in ice bath:
5 times of first chain buffer (5 × First-Strand buffer) 4uL；1 μ L of reverse transcriptase (M-MLV).React item
Part: 42 DEG C of warm bath 50min, 85 DEG C of heating 5min terminate reaction.
C. it takes 2-3 μ L to be directly used in PCR and reacts or be stored in -20 DEG C.
(2) semiquantitive PCR amplifying target genes
A. following reaction system is added in PCR pipe in order on ice:
cDNA 2.5μL；1 μ L of forward primer (Forward primer) (10mM)；Reverse primer (Reverse primer)
(10mM)1μL；2 times of PCR premix enzyme (2 × Taq PCR Mix) 12.5 μ L；Distilled water (ddH2O it) mends to 25 μ L.
B.PCR reaction cycle condition
It is recycled by following temperature:
1) 94 DEG C of 5min of initial denaturation；2) 94 DEG C of 30s are denaturalized；3) anneal 61 DEG C of 30s；4) extend 72 DEG C of 1min；5) it repeats
2-4 step 30 circulation；6) extend 72 DEG C of 5min；7) 4 DEG C of preservations.
C. result detects: taking 5 μ L reaction products after reaction, carries out agarose gel electrophoresis separation identification.
Claims (8)
1. a kind of Schiff base derivatives, it is characterised in that the structural formula of the Schiff base derivatives are as follows:
2. the method for preparing chemical combination described in claim 1, characterized by the following steps:
I) using nepal Gold methyl ester as raw material, by itself and N- piperidine ethanol, triphenylphosphine dissolved is cooled to zero in tetrahydrofuran
Degree, then diisopropyl azodiformate is slowly added dropwise, and reaction is finally stirred at room temperature overnight, obtains intermediate (II):
Ii intermediate (II) and hydration hydrazine reaction 12h) are obtained into intermediate (III):
Iii intermediate (III)) is reacted into 12h with 4- nitryl furfural and obtains compound described in claim 1:
3. a kind of Schiff bases compound and its pharmaceutically acceptable salt are preparing the application in anticancer drug.
4. application according to claim 3, wherein the cancer includes colon cancer.
5. application according to claim 3, wherein the cancer includes breast cancer.
6. application according to claim 3, wherein the cancer includes leukaemia.
7. application according to claim 3, wherein the cancer includes lung cancer.
8. application according to claim 3, wherein the cancer includes extremely relevant to STAT3 cellular signal transduction
Every other cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811299205.9A CN109369579A (en) | 2018-10-22 | 2018-10-22 | A kind of preparation of new compound and its application in terms for the treatment of of cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811299205.9A CN109369579A (en) | 2018-10-22 | 2018-10-22 | A kind of preparation of new compound and its application in terms for the treatment of of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109369579A true CN109369579A (en) | 2019-02-22 |
Family
ID=65397236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811299205.9A Pending CN109369579A (en) | 2018-10-22 | 2018-10-22 | A kind of preparation of new compound and its application in terms for the treatment of of cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109369579A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113336729A (en) * | 2021-05-31 | 2021-09-03 | 四川大学华西医院 | Nifuratel derivatives, and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102961374A (en) * | 2012-12-12 | 2013-03-13 | 苏州大学 | Application of compound and STAT3 (Signal Transducer and Activator of Transcription) inhibitor |
| WO2018183908A1 (en) * | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
-
2018
- 2018-10-22 CN CN201811299205.9A patent/CN109369579A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102961374A (en) * | 2012-12-12 | 2013-03-13 | 苏州大学 | Application of compound and STAT3 (Signal Transducer and Activator of Transcription) inhibitor |
| WO2018183908A1 (en) * | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113336729A (en) * | 2021-05-31 | 2021-09-03 | 四川大学华西医院 | Nifuratel derivatives, and preparation method and application thereof |
| CN113336729B (en) * | 2021-05-31 | 2022-05-27 | 四川大学华西医院 | Nifuratel derivatives, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108498503A (en) | The preparation and use of a kind of novel cell signal transduction and 3 type of the gene transcriptional activation factor (STAT3) inhibitor | |
| CN109369579A (en) | A kind of preparation of new compound and its application in terms for the treatment of of cancer | |
| Bansode et al. | Potentially antibreast cancer enamidines via azide–alkyne–amine coupling and their molecular docking studies | |
| Sajid et al. | Antitumour compounds from a saline soil isolate, Streptomyces griseoincarnatus CTF15 | |
| CN107190052B (en) | The purposes of LOC101928926 gene | |
| CN109316479A (en) | The preparation and its application in terms for the treatment of of cancer of a kind of novel naphthol compound | |
| CN109180621A (en) | The preparation and the application in terms for the treatment of of cancer of a kind of New Schiff Base class compound | |
| CN103313707A (en) | Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions | |
| CN105693636A (en) | Synthesis and application of Cu(mtyp)2 with antitumor activity | |
| CN109053480A (en) | The preparation method of a kind of novel niclosamide derivative and the application in oncotherapy | |
| CN112870363B (en) | Application of human PCID2 protein in preparation or screening of antitumor drugs and compound with antitumor activity | |
| CN108997319A (en) | Thiocarbamoyl imidazole alkanone derivative and its synthetic method and application | |
| CN107827854B (en) | Biomarker for marking malignant tumor cells, preparation method and application thereof | |
| CN105997992B (en) | Compound DY1 is preparing the application in anti-large intestine cancer drug | |
| CN109988125A (en) | The preparation method of a kind of novel benzophenone amine compounds and the application in oncotherapy | |
| CN104910074A (en) | Hydroximic acid group-containing pyrazoles derivative, preparation method and purpose thereof | |
| CN109535101A (en) | The preparation method of a kind of novel salicyclic acid derivatives and its application in terms of oncotherapy | |
| Rajasekar et al. | Mycogenic Synthesis of gold nanoparticles mediated by the endophytic fungi Colletotrichum gloeosporioides, with special reference to In Vitro and In Silico studies | |
| CN110818719A (en) | Synthesis method and application of binaphthol-troglium amine Schiff base derivative for preparing antitumor drug | |
| Liu et al. | Anticancer Activity of Zn (II) Coordination Polymer Against Cervical Cancer Cells via miR-5571/MDM2 | |
| CN107556309B (en) | Pharmaceutical application of polysubstituted tetrahydronaphthyridine compound and preparation method thereof | |
| CN107502659A (en) | Application of the VIPR1 genes in diagnosing cancer of liver product and prognosis prediction product is prepared | |
| CN106047874A (en) | Dnazyme molecule of targeted SALL4 gene and application thereof in breast cancer gene therapy | |
| CN102924425B (en) | Homopiperony lamine 3-methyl-5-chlorine salicylide and synthesis method and application thereof | |
| CN102942554B (en) | Homopiperony lamine condensed salicylaldehyde and synthesis method and application of homopiperony lamine condensed salicylaldehyde |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190222 |